Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cadrenal Therapeutics, Inc. (CVKD : NSDQ)

• Company Description    Cadrenal Therapeutics Inc. is a biopharmaceutical company. It focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. Cadrenal Therapeutics Inc. is based in PONTE VEDRA, Fla. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $13.00 Daily Weekly Monthly 20 Day Moving Average: 32,920 shares Shares Outstanding: 1.97 (millions) Market Capitalization: $25.57 (millions) Beta: 0.95 52 Week High: $22.90 52 Week Low: $5.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.28% -16.52% 12 Week -22.39% -34.72% Year To Date -10.28% -15.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 822 A1A North Suite 306 - Ponte Vedra,FL 32082 USA ph: 904-300-0701 fax: - cadrenal@lythampartners.com http://www.cadrenal.com

• General Corporate Information    Officers Quang X. Pham - Chairman and Chief ExecutiveOfficer Matthew Szot - Chief Financial Officer John R. Murphy - Director Glynn Wilson - Director Steven Zelenkofske - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 127636207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 1.97 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.95 Market Capitalization: $25.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.13 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -39.40% vs. Previous Quarter: 23.72% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -244.94 12/31/24 - -202.53 ROA 06/30/25 - - 03/31/25 - -181.94 12/31/24 - -156.01 Current Ratio 06/30/25 - - 03/31/25 - 4.32 12/31/24 - 3.77 Quick Ratio 06/30/25 - - 03/31/25 - 4.32 12/31/24 - 3.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.15 12/31/24 - 4.17 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©